Antengene Announces XPOVIO® Regulatory Approval in Macau for the Treatment of Relapsed and/or Refractory Multiple Myeloma
XPOVIO® has received regulatory approvals in 42 countries and regions including Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore and Australia.
- XPOVIO® has received regulatory approvals in 42 countries and regions including Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore and Australia.
- XPOVIO® is the world's first oral selective inhibitor of the nuclear export protein XPO1, with regulatory approvals in 42 countries and regions including Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore and Australia.
- "Antengene is excited to receive approval of XPOVIO® in Macau, first in the next wave of expected approvals in the APAC."
- I am glad that XPOVIO® has become the first and only XPO1 inhibitor approved for the treatment of patients with R/R MM in Macau China.